TerraPower Isotopes and PanTera signed a strategic collaboration that they say will increase the global availability of actinium-225 (Ac-225), a radioisotope that may prove able to treat a large variety of cancer indications.
Through the collaboration, the companies will work to increase near-term production of Ac-225 to support ongoing clinical trials, as well as support large-scale supply of the radioisotope in the long term to meet global demand.
The companies will use TerraPower Isotope's natural decay method based on thorium-229 (Th-229) and PanTera's "Gamma route" based on the Rhodotron and radium-226 to produce Ac-225.
